Director Stephen Denelsky Buys $48.7K in Stock, Joining Recent Insider Accumulation
Summary
Director Stephen Denelsky purchased $48,700 worth of Harvard Bioscience common stock, marking the second director purchase in two days and signaling insider confidence after recent negative financial news.
Key Events
-
Director Increases Stake
Director Stephen Denelsky acquired 10,000 shares of common stock for $48,700 in an open market purchase on March 17, 2026, at a price of $4.87 per share.
-
Follows Recent Insider Buying
This purchase marks the second director buying activity in two days, following Director William Snider's $103,604 purchase yesterday, indicating a cluster of insider accumulation.
-
Post-Split Holdings
The transaction occurred after the company's 1-for-10 reverse stock split on March 13, 2026, with Denelsky's post-transaction direct holdings totaling 21,000 shares.
-
Context of Recent Financials
The insider buying follows the company's recent report of a $56.7 million net loss for FY2025, including a $48.0 million goodwill impairment, and a reverse stock split.
Analysis
Director Stephen Denelsky's open market purchase of $48,700 in Harvard Bioscience common stock signals confidence following the company's recent reverse stock split and significant net loss. This transaction, combined with another director's purchase yesterday, indicates a cluster of insider buying. Such accumulation can be a positive sign for investors, suggesting that management sees value despite recent challenges and a period of negative news.
At the time of this filing, HBIO was trading at $4.77 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $21.3M. The 52-week trading range was $2.81 to $9.46. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.